TNFAIP3 and systemic sclerosis: Impaired A20 expression or function in SSc patients due either to TNFAIP3 genetic variants and/or environmental regulatory influences resulting in altered DREAM expression might contribute directly to the development or progression of fibrosis in multiple organs and represents a novel target for anti-fibrotic therapy.